Form 4: Catalyst Pharmaceuticals Chief Strategy Officer Acquires Stock Options and Restricted Stock Units

Preethi Sundaram, Chief Strategy Officer of Catalyst Pharmaceuticals, acquired stock options and restricted stock units, increasing her beneficial ownership in the company.

Summary

• Preethi Sundaram, Chief Strategy Officer at Catalyst Pharmaceuticals, has reported the acquisition of stock options and restricted stock units.
• On November 21, 2024, Sundaram acquired options to purchase 137,553 shares of common stock at an exercise price of $21.12.
• These options vest in three equal tranches on November 21, 2025, 2026, and 2027.
• Additionally, Sundaram acquired 16,809 restricted stock units, each representing a contingent right to receive one share of common stock upon vesting.
• Following these transactions, Sundaram's total direct holdings increased to 691,812 options and 708,621 restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment due to the increase in executive ownership, which is generally seen as a good sign for the company's future. However, it is a routine filing and not a major event.

Positives

• The acquisition of stock options and restricted stock units by a key executive signals confidence in the company's future performance.
• The vesting schedule of the options and restricted stock units aligns the executive's interests with the long-term success of the company.

Future Outlook

The vesting schedule of the options and restricted stock units suggests a long-term commitment from the executive.

Industry Context

This is a standard practice for executive compensation in publicly traded companies, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are common forms of executive compensation in the pharmaceutical industry.
• Companies like Biogen, Amgen, and Gilead Sciences also use similar equity-based compensation to incentivize their executives.
• The vesting schedule of three years is also a typical practice to ensure long-term commitment.

Stakeholder Impact

• The increased ownership by a key executive may positively influence investor confidence.
• The vesting schedule aligns the executive's interests with the long-term success of the company, which benefits shareholders.

Key Dates

Keywords

Catalyst Pharmaceuticals, stock options, restricted stock units, insider trading, executive compensation, Preethi Sundaram, CPRX